On Apr. 2, 2020, Cerus announced that the University Hospital Basel transfused the first two COVID-19 patients with INTERCEPT treated coronavirus convalescent plasma (CCP). Cerusﾒ field team supported the INTERCEPT system implementation which was completed in one week.

The University Hospital Basel and the Swiss Red Cross, Basel initiated one of the first CCP programs outside of China and are leveraging the INTERCEPT pathogen-reduction technology to enhance plasma transfusion safety and enable collections from convalesced donors earlier after their infection than might otherwise be possible.